Paper Details

  1. Home
  2. Paper Details

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.

Author: BaekMarshall, BrownJennifer R, ByrdJohn C, ChernyukhinNataliya, ChristianBeth, DyerMartin J S, FurmanRichard R, GhiaPaolo, HamdyAhmed M, HillmenPeter, IzumiRaquel, JurczakWojciech, LezhavaTamara, O'BrienSusan M, OwenRoger G, PagelJohn M, PatelPriti, RuleSimon, SharmanJeff P, StephensDeborah M, StreetlyMatthew J, SunClare, WangMichael

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Acalabrutinib, a highly selective BTK inhibitor, is effective for many B-cell malignancies. This pooled analysis of 1040 patients evaluated the tolerability of acalabrutinib monotherapy across nine clinical studies. The most common adverse events were headache, diarrhea, upper respiratory tract infection, contusion, nausea, fatigue, and cough. Serious adverse events occurred in 39%, with pneumonia being the most frequent. Overall, acalabrutinib demonstrated good tolerability with no new late toxicities identified, supporting its use for long-term treatment of mature B-cell malignancies.
Paper Details　
Original Abstract of the Article :
Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor. To characterize acalabrutinib tolerability, we pooled safety data from 1040 patients with mature B-cell malignancies tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/s41375-021-01252-y

データ提供：米国国立医学図書館（NLM）

Acalabrutinib: A Promising Treatment for Mature B-Cell Malignancies

The field of hematologic malignancies is constantly evolving, with new therapies emerging to combat these complex diseases. This study investigates the safety and efficacy of acalabrutinib, a next-generation Bruton tyrosine kinase (BTK) inhibitor, in patients with mature B-cell malignancies. The research team utilized a pooled analysis of data from nine clinical trials, encompassing a diverse group of 1040 patients. This approach allowed for a comprehensive evaluation of acalabrutinib's tolerability and potential side effects.

Acalabrutinib's Tolerability: A Detailed Look

The results reveal a favorable safety profile for acalabrutinib. While some common adverse events (AEs) were observed, such as headache, diarrhea, and upper respiratory tract infections, these were generally manageable. The study also found that serious AEs (SAEs) occurred in 39% of patients, with pneumonia being the most prevalent SAE, affecting 6% of the participants. Notably, only 9% of patients discontinued treatment due to AEs. This suggests that acalabrutinib offers a well-tolerated treatment option for patients with mature B-cell malignancies.

Navigating Potential Side Effects: What Patients Should Know

While acalabrutinib demonstrates promising tolerability, it's crucial to be aware of potential side effects. Infections, hemorrhages, and neutropenia are among the most frequent AEs. This highlights the importance of close monitoring during treatment and prompt management of any complications that arise. Patients should discuss any concerns or potential risks with their healthcare providers to make informed decisions about their treatment plan.

Dr. Camel's Conclusion

This study paints a positive picture of acalabrutinib as a potential long-term treatment option for patients with mature B-cell malignancies. It's encouraging to see a drug with a favorable safety profile, offering hope for patients seeking effective treatment options. However, it's important to recognize that this is just one study, and further research is needed to fully understand the long-term implications of acalabrutinib therapy. Imagine a camel caravan crossing the vast desert - just as the caravan relies on a steady supply of water and provisions, patients need careful monitoring and management of their health throughout their treatment journey.

Date :
  1. Date Completed 2021-12-30
  2. Date Revised 2022-10-18
Further Info :

Pubmed ID

33907299

DOI: Digital Object Identifier

10.1038/s41375-021-01252-y

Related Literature

Article Analysis
・Side Effects of acalabrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.